HR and breast carcinoma: Among the eligible patients, the distribution of breast cancer subtypes was as follows: 340 (45.7%) HR+/HER2−, 148 (19.9%) HR−/HER2+, 131 (17.6%) HR+/HER2+, and 125 (16.8%) HR−/HER2−.